Big Pharma Enters the Supercomputer Race

Leading pharmaceutical companies are investing heavily in artificial intelligence and supercomputers to accelerate drug discovery.

Bristol Myers Squibb (BMS) is expanding its partnership with Nvidia to build one of the most powerful AI computing systems in the pharmaceutical industry. The technology will help researchers analyze large amounts of scientific data, identify promising molecules and speed up drug development.

Eli Lilly and Roche are also developing advanced AI infrastructure with Nvidia.

BMS plans to make the new system available to researchers in the first quarter of 2027.

The goal is not simply to have the most powerful supercomputer, but to use AI to develop new medicines faster, more accurately and more efficiently.